NEWS

Press Releases

June 11, 2020

Dyne Therapeutics Appoints Daniel Wilson as Vice President, Head of Intellectual Property

May 19, 2020

Dyne Therapeutics Accelerates Programs in Facioscapulohumeral Muscular Dystrophy (FSHD) with Exclusive Licensing of Technologies to Target Genetic Basis of FSHD and Expanded Scientific Advisory Board

May 12, 2020

Dyne Therapeutics Demonstrates FORCETM Platform’s Potential to Deliver Potent Exon-Skipping Molecules Directly to Muscle to Treat Duchenne Muscular Dystrophy

May 11, 2020

Dyne Therapeutics Announces Appointment of Debra Feldman as Vice President, Head of Regulatory

April 23, 2020

Dyne Therapeutics Appoints David Lubner to Board of Directors

March 31, 2020

Dyne Therapeutics Announces Equity Investment from CureDuchenne Ventures to Support Pioneering Approach to Restoring Muscle Health in DMD

February 06, 2020

Dyne Therapeutics Expands Leadership Team with Key Hires

January 13, 2020

Dyne Therapeutics Announces Appointment of Molly White as Vice President, Medical Communications and Advocacy

Dyne Posters and Publications

May 12, 2020

Targeted Delivery of ASOs Demonstrates Potential to Treat Duchenne Muscular Dystrophy
Presented at ASGCT 2020

Supporting Literature

Platform


Development of Antibody-siRNA Conjugate Targeted to Cardiac and Skeletal Muscles
Journal of Controlled Release

Metabolic Catastrophe in Mice Lacking Transferrin Receptor in Muscle
EBio Medicine

DM1


Targeting Nuclear RNA for In Vivo Correction of Myotonic Dystrophy
Nature

Identification and Characterization of Modified Antisense Oligonucleotides Targeting DMPK in mice and nonhuman primates for the treatment of Myotonic Dystrophy Type 1
Nucleic Acids Research (NAR)

In Situ Fluorescence Analysis Demonstrates Active siRNA Exclusion From the Nucleus by Exportin 5
Nucleic Acids Research (NAR)

RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus
Molecular Therapy

The Current State and Future Directions of RNAi-based Therapeutics
Nature Reviews Drug Discovery

Quantitative Fluorescence Imaging Determines the Absolute Number of Locked Nucleic Acid Oligonucleotides Needed for Suppression of Target Gene Expression
Nucleic Acids Research (NAR)

Cellular Localization of Long Non-Coding RNAs Affects Silencing by RNAi More Than by Antisense Oligonucleotides
Nucleic Acids Research (NAR)

RNAi Factors Are Present and Active in Human Cell Nuclei
Cell Reports

RNA-mediated Therapies in Myotonic Dystrophy
Drug Discovery Today

Dmpk Gene Deletion or Antisense Knockdown Does Not Compromise Cardiac or Skeletal Muscle Function in Mice
Human Molecular Genetics

FSHD


Morpholino-Mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics
Molecular Therapy

Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD)
Genes

Stay connected

Follow us on Twitter and LinkedIn.

Email: info@dyne-tx.com